-
サマリー
あらすじ・解説
In this important podcast episode, we interview Victor Bulto, President, US for Novartis, to discuss the company's efforts to develop groundbreaking treatments while ensuring accessibility and affordability for patients. We delve into how the pharmaceutical industry navigates numerous post-FDA approval barriers to launch new drugs and the importance of market access, patient support services, and a commitment by manufacturers to provide patient assistance and other support for patients.
Victor Bulto, President, Novartis
Novartis
FDA
Institute for Clinical and Economic Review (ICER)
American Heart Association (AHA)
Inflation Reduction Act (IRA)
Pharmacy Benefit Manager (PBM)
Medicare
Medical terminology referenced in this episode:
Cell therapy: CART-T
Radioligand therapy
RNA
Entresto
Molecular glues
Targeted protein degradation
Antisense oligonucleotides
Small interfering RNAs: siRNAs
LDL cholesterol
COVID
Hematological malignancies
Refractory autoimmune diseases
Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.